Medical devices, healthcare technology and the business of care
510(k) clearance · K260233

Elecsys EBV IgM

Roche Diagnostics · Decision date Oct 2, 2026

MEDTECHLEDGER EXPLANATIONK260233

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on 2026-10-02 for Elecsys EBV IgM, submitted by Roche Diagnostics of Indianapolis, Indiana, under 510(k) number K260233. The device falls under regulation 866.3235, classification product code LJN, with subsequent product codes LLM and LSE, in the Microbiology specialty and review panel. The application was received 01/26/2026 and reviewed as a traditional 510(k) without third-party review, combination product status or an authorized predetermined change control plan.

SESE indicates 510(k) clearance, not premarket approval. The public record does not describe the assay's components, intended use, performance data or comparison predicate, so the basis for the equivalence finding remains unknown from these sources. A separate FDA listing shows related Roche submissions decided the same day, K260221 for Elecsys EBV EBNA IgG and K260232 for Elecsys EBV VCA IgG, but the record does not state whether these were reviewed together or share a predicate.

No clinical or analytical claims should be inferred from the clearance alone.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Oct 2, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K260233
Regulatory pathway
510(k) premarket notification
Product code
LJN
Decision code
SESE
Decision date
Oct 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Antibody Igm, If, Epstein-Barr Virus.

Product code
LJN
FDA device class
1

FDA decision timeline

  1. K260233 received

    Application receipt date recorded by FDA.

  2. K260233 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Diagnostics

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Indianapolis, IN

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records